Gilead Just Dropped $5 Billion on a German Startup You've Never Heard Of
Gilead is spending up to $5 billion to acquire Tubulis, a German ADC startup that went from a Munich university lab to biotech's hottest takeover target in just seven years. The deal reveals how antibody-drug conjugates have become pharma's most competitive M&A battleground.
Two scientists spun a company out of a Munich university lab in 2019. Seven years later, Gilead Sciences is paying up to $5 billion to buy it. That's the kind of trajectory that makes founders in Cambridge and San Francisco quietly Google their net worth.
The target is Tubulis GmbH, a German biotech that builds antibody-drug conjugates (ADCs): basically guided missiles that deliver cancer-killing payloads directly to tumor cells. Gilead is paying $3.15 billion upfront in cash and dangling another $1.85 billion in milestone payments down the road. The deal closed in Q2 2026, and it says everything about where the cancer drug market is headed.
From University Lab to Billion-Dollar Buyout
Tubulis was co-founded by Dr. Dominik Schumacher and Dr. Jonas Helma-Smets, who developed their ADC technology at LMU Munich and the Leibniz Research Institute in Berlin. The idea started percolating around 2015, but the company didn't officially leave the university until 2019.
From there, the funding escalated fast. A modest ~$12 million Series A in 2020. A $63 million Series B in 2022. A €128 million Series B2 in 2024. Then a massive $360 million Series C in October 2025, led by Venrock.
That's a lot of capital for a company with zero approved products. But Tubulis wasn't just building drugs; it was building a platform.
The Secret Sauce: Making Better Guided Missiles
ADCs are one of the hottest drug categories in oncology right now. Think of them like a postal service for poison: you attach a cell-killing chemical (the payload) to an antibody that knows exactly which cells to find. The antibody delivers the payload to the tumor, sparing healthy tissue.
The problem? Many ADCs are unstable. The payload detaches too early, causing side effects. Or the drug doesn't carry enough payload to do the job.
Tubulis built proprietary technology to solve both problems. Its P5 conjugation chemistry (branded as Tubutecan) creates ADCs that are unusually stable and can carry a , meaning each antibody is loaded with more firepower. A second platform called modifies the antibody itself to create a better environment for the payload, like reinforcing the delivery truck so nothing falls out in transit.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
drug-to-antibody ratio of 8
Tub-tag
The company's lead candidate, TUB-040, targets a protein called NaPi2b that's overexpressed in platinum-resistant ovarian cancer and certain lung cancers. It's currently in a Phase 1b/2 trial. A second candidate, TUB-030, targets a different protein (5T4) across a broader range of solid tumors and is also in early clinical testing.
Beyond those two, Tubulis has a handful of earlier-stage programs, including some intriguing "degrader antibody conjugates" that could expand what ADCs are capable of delivering.
Why Gilead Is All-In on Cancer Missiles
Gilead used to be synonymous with HIV drugs. Not anymore. The company has been on a deliberate, multi-year shopping spree to transform itself into an oncology powerhouse, and the receipts are staggering.
It started with the $21 billion acquisition of Immunomedics in 2020, which brought in Trodelvy, a blockbuster ADC for breast cancer. Then came the cell therapy side: Gilead already owned Kite Pharma (bought in 2017 for its CAR-T technology) and doubled down in 2025 by acquiring Arcellx for roughly $7.8 billion.
In 2025 alone, Gilead executed three major acquisitions totaling approximately $14–15 billion: Arcellx (CAR-T), Ouro Medicines (immunology, up to ~$2.2 billion), and the Tubulis deal. Gilead's oncology business already generates over $3 billion in annual revenue, and these purchases are designed to keep that number climbing.
The Tubulis acquisition is the clearest signal yet that Gilead views ADCs as a core pillar of its future, not a one-off bet. With Trodelvy providing commercial ADC experience and Tubulis providing next-generation platform technology, Gilead is building what looks like a full-stack ADC operation. Munich will even become "The Tubulis ADC Innovation Center" within Gilead, serving as its hub for ADC discovery and manufacturing.
The ADC Gold Rush Is Real
Gilead isn't the only pharma giant writing massive checks for ADC technology. The sector has become one of biotech's most competitive M&A arenas.
Pfizer paid $43 billion for Seagen in 2023, the single largest ADC-focused acquisition ever. AbbVie spent $10.1 billion on ImmunoGen. AstraZeneca paid $1.35 billion upfront in its initial collaboration deal for access to Daiichi Sankyo's deruxtecan ADC portfolio, and Merck committed $4 billion upfront (up to $22 billion total) for three Daiichi Sankyo ADCs.
The numbers at the market level are just as eye-popping. Analysts estimate the global ADC market hit roughly $15–16 billion in 2025 and could reach $18–22 billion or more in 2026. Some long-range projections see it topping $70 billion by 2031. The average size of ADC licensing deals nearly doubled from about $740 million in 2024 to $1.5 billion by mid-2025.
Manufacturing is scaling to match. AstraZeneca announced a $1.5 billion ADC manufacturing plant in Singapore in 2024. Eli Lilly committed $5 billion to ADC production facilities in 2025. When companies start building factories, you know the bet isn't speculative anymore.
What Wall Street Thinks
Analyst reaction to the Tubulis deal was broadly positive, though not euphoric. RBC Capital Markets called it a "strategically sound bolt-on" and bumped its Gilead price target from $118 to $123, while keeping a Sector Perform rating. That's the Wall Street equivalent of a polite nod.
Other firms were more enthusiastic about Gilead's overall trajectory. Cantor Fitzgerald maintained an Overweight rating with a $155 target. UBS held its Buy rating at $155. Deutsche Bank echoed with Buy and $155, projecting strong revenue momentum from Gilead's broader portfolio.
The general consensus: this deal makes strategic sense, adds differentiated ADC technology, and fits Gilead's pattern of "partner early, build conviction, then acquire." Gilead initially partnered with Tubulis in 2024 before converting that relationship into a full buyout.
The Bigger Picture
Gilead's management has signaled that after this 2025 deal spree, the company will shift focus toward integration and execution. Translation: the shopping cart is full; now it's time to cook.
The question is whether Tubulis's platform technology can produce the kind of clinical wins that justify a $5 billion price tag. TUB-040 is still in early-stage trials, and the $1.85 billion in milestones likely hinges on results that are years away.
But that's the bet Gilead is making, and it's one the entire industry seems to agree on: ADCs aren't a fad. They're becoming the backbone of modern cancer treatment. And if you've built a better way to make them, somebody with very deep pockets is going to come knocking.
Deals & M&A5 min read
UCB Just Bet $1.15 Billion That Brain Cells Can Stop Seizures
UCB is spending up to $1.15 billion on Neurona Therapeutics and its lab-grown brain cell therapy for drug-resistant epilepsy. The early clinical data is stunning, but the real test is just getting started.
